Medical Education Library

Distinguishing among incretin-based therapies

This supplement was sponsored by the Primary Care Metabolic Group and the Primary Care Education Consortium and is supported by a grant from Novo Nordisk Inc.


The number of pharmacologic options available to treat type 2 diabetes mellitus has grown considerably over the past decade. With these options, health care providers have new opportunities to individualize treatment and provide better control of patients’ blood glucose levels. The “treat to failure” approach has been replaced by a “treat to target” approach, with the purpose of quickly achieving the A1C goal of <7.0% in most people, and then intensifying or changing therapy as needed to maintain glycemic control.

Next Article: